Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
High-priced outpatient drugs are causing a sharp rise in the “catastrophic” coverage of Medicare’s Part D drug benefit, where the government picks up most of the tab, according to a government watchdog agency report released Jan. 5.
Federal payments for Medicare’s catastrophic coverage more than tripled, growing from $10.8 billion to $33.2 billion between 2010 and 2015, the Department of Health and Human Services Office of Inspector General found.
Ten drugs accounted for a third of spending in the catastrophic phase of the Part D benefit, which beneficiaries enter when their spending reaches a threshold. The 10 include two drugs used to treat hepatitis C, Harvoni and Sovaldi, manufactured by Gilead Sciences.
Members of Congress and others have raised concerns about the high prices of certain drugs and the impact these have on Medicare beneficiaries, the study said. “Understanding the effect that high drug prices have on spending in catastrophic coverage is crucial,” the report said.
The Part D benefit has an initial coverage limit for beneficiaries, followed by a coverage gap. Enrollees remain in the gap—or doughnut hole—until their out-of-pocket spending reaches the catastrophic coverage limit, at which point Medicare picks up most of the tab.
Congress’s Medicare advisers recommended last year that some of the responsibility for spending in the catastrophic phase be shifted from taxpayers to drug plans.
Those advisers, the Medicare Payment Advisory Commission, in April 2016 urged Congress to lower Medicare’s reinsurance subsidy from 80 percent to 20 percent as part of a slate of policy recommendations to update the Part D benefit, which was launched in 2006.
The current design was intended to protect plans from catastrophic losses. But the MedPAC commissioners said that having the government pay for the growing cost of reinsurance is a disincentive for plans to take a more aggressive role in managing drug spending.
However, the recommendations haven’t been acted upon by Congress.
The HHS inspector general report “reiterates what MedPAC put out” in 2016, Kelly Brantley, a vice president at Avalere Health, a Washington-based consultancy, told Bloomberg BNA.
For the past decade, Part D has “flown under the radar” as noncontroversial in part because of low premiums and enrollee satisfaction, she said.
However, with the new administration and Republican Congress, “entitlement reform is something that could be on the table,” Brantley said. When that option is combined with pressure from the public to do something on rising drug costs, “some element of Part D could be at risk for change,” she said.
The report is a reminder that “there may be trade-offs necessary in the Part D construct and benefit design” to address the escalating costs of reinsurance, Larry Kocot of consulting firm KPMG said. Kocot is principal and national leader, Center for Healthcare Regulatory Insight, at KPMG.
He told Bloomberg BNA that “Congress will have to make the decision as to what tools they will provide to CMS or plans to increase competition to address high costs.”
The HHS OIG praised the Centers for Medicare & Medicaid Services for publishing information about drug prices, as a push toward transparency, and for asking the pharmaceutical industry to find solutions toward affordability.
“Moving forward, CMS will likely need additional tools to address these issues,” the OIG said.
Potential tools include restructuring the Part D benefit so that sponsors have more incentives and opportunities to lower costs, creating more transparency about drug pricing, promoting value-based options and revising the law to allow the federal government to negotiate prices for certain drugs.
The report’s finding should be “taken with a grain of salt,” Ellyn Sternfield, a health-care attorney with Mintz Levin in Washington, told Bloomberg BNA.
For example, the OIG uses total spending numbers, which don’t take into account any rebates or other price concessions that may have been offered by the drug manufacturers, Sternfield said.
The association representing pharmaceutical manufacturers also objected to the findings as misleading.
“It is unfortunate that the report continues to showcase misleading, un-rebated spending figures for ten innovative products that have brought significant advances to the treatment of serious health conditions,” Allyson Funk, senior director, communications, with the Pharmaceutical Research and Manufacturers of America, told Bloomberg BNA.
Sternfield also said many of the drugs highlighted in the report, such as those designed to treat hepatitis C, are curative.
“There is no mention of the money saved in terms of a lifetime of treatment costs, in exchange for a few months of coverage of drug costs,” she said.
However, Sternfield said she does think there will be ongoing pressure on Congress and the incoming Trump administration to address drug costs.
Insurers and drug manufacturers are aware of the issues arising from higher drug costs, but the existing enforcement structure blocks any attempts to come up with new drug pricing methodologies, Sternfield said.
“For example, the OIG recommends exploring value-based options for drug coverage, but creating a reimbursement methodology that incentivizes the value of treatment to the patient runs the risk of someone being accused in a qui tam [whistle-blower case] of unlawful beneficiary inducements or kickbacks,” she said.
To contact the editor responsible for this story: Kendra Casey Plank at firstname.lastname@example.org
The inspector general's report on Part D spending is at http://src.bna.com/laB.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)